AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
Price Chart
Executive Summary
Ascentage Pharma filed a 6-K furnishing its third amended and restated memorandum and articles of association (adopted May 20, 2026), poll results from its AGM (all resolutions passed, including approval of RSU/option grants to executives and a share repurchase mandate), and two clinical data announcements. The company released six abstracts (3 rapid oral, 3 poster) for ASCO 2026 covering its three lead drug candidates — olverembatinib, lisaftoclax, and alrizomadlin — across multiple hematologic and solid tumor indications. The data show encouraging efficacy signals (e.g., 91.3% CCyR rate for olverembatinib in second-line CP-CML; 30% ORR for alrizomadlin + lisaftoclax in pediatric sarcomas) and ongoing global Phase III registrational trials (POLARIS-2, GLORA). This is a routine pipeline update with no financial results or material corporate events.
Actionable Insight
The ASCO 2026 data are incrementally positive for olverembatinib's CML franchise and lisaftoclax's CLL/SLL program, but all drugs remain investigational in the US and no regulatory milestones were announced. The AGM approvals (share issuance/repurchase mandates, charter amendments) are routine governance. Monitor upcoming ASCO presentations (May 29–June 2) for investor reaction and any subsequent regulatory updates on POLARIS-2 or GLORA enrollment.
Key Facts
- Six abstracts accepted at ASCO 2026 (May 29–June 2): 3 rapid oral, 3 poster presentations.
- Olverembatinib + blinatumomab Phase Ib: 4/5 MRD+ patients achieved CR, 2 achieved MRD negativity in R/R Ph+ BCP-ALL/CML-LBP.
- Olverembatinib second-line CP-CML (n=42 evaluable): CCyR 91.3%, MMR 60.9% at cycle 24; 81.3% CCyR in patients failing second-gen TKIs.
- Alrizomadlin ± lisaftoclax in pediatric sarcomas: monotherapy CR in 1 RMS patient; combination ORR 30%, DCR 80%, no DLTs.
- Olverembatinib in SDH-deficient GIST (n=26): 23.1% PR, median PFS 25.7 months; first evidence of p38-CD36 pathway inhibition.
- Global Phase III POLARIS-2 (olverembatinib in CML) and GLORA (lisaftoclax + BTKi in CLL/SLL) trials are actively enrolling.
- AGM held May 20, 2026: all 10 resolutions passed, including adoption of amended charter, share issuance mandate (20%), share repurchase mandate (10%), and RSU/option grants to CEO Dr. Yang Dajun and CMO Dr. Zhai Yifan.
- Third amended and restated memorandum and articles of association adopted by special resolution on May 20, 2026.
- No financial results, guidance, or material corporate transactions reported in this filing.
Financial Impact
No financial figures reported. Clinical data updates are non-financial and do not change revenue or earnings outlook.
Risk Factors
- All three lead candidates (olverembatinib, lisaftoclax, alrizomadlin) are not yet FDA-approved; clinical data are early-stage and non-registrational for most indications.
- POLARIS-2 and GLORA Phase III trials are still enrolling; no efficacy or safety readouts provided in this filing.
- Stock has underperformed significantly (avg T+20 alpha -17.31% over last 8 settled reports), suggesting limited market responsiveness to pipeline updates.
- AGM approved a 20% share issuance mandate and RSU/option grants to executives, creating potential future dilution.
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060305 |
| Document: ea029178201ex99-3.htm | 0001213900-26-060305 |
| Document: ea029178201ex99-1.htm | 0001213900-26-060305 |
| Document: ea029178201ex99-4.htm | 0001213900-26-060305 |
| Document: ea0291782-6k_ascentage.htm | 0001213900-26-060305 |
| Document: 0001213900-26-060305-index-headers.html | 0001213900-26-060305 |
| Document: 0001213900-26-060305-index.html | 0001213900-26-060305 |
| Document: 0001213900-26-060305.txt | 0001213900-26-060305 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
9d ago
|
6-K
| $19.08 $17.20 | ▼ −9.85% | ▼ −7.10% | $17.07 (−10.53%) |
|
May 28, 2026
12d ago
|
6-K
| $20.01 $17.20 | ▼ −14.04% | ▼ −11.52% | $17.07 (−14.69%) |
|
May 28, 2026
13d ago
|
6-K
| $19.88 $17.87 | ▼ −10.11% | ▼ −10.06% | $17.07 (−14.13%) |
|
May 22, 2026
19d ago
|
6-K
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.86% | $17.07 (−18.75%) |
|
May 22, 2026
19d ago
|
Press Release
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.84% | $17.07 (−18.75%) |
|
May 13, 2026
28d ago
|
6-K
| $21.38 $18.99 | ▼ −11.18% | ▼ −10.02% | $17.07 (−20.16%) |
|
May 12, 2026
29d ago
|
6-K
| $21.16 $18.56 | ▼ −12.29% | ▼ −12.37% | $17.07 (−19.33%) |
|
Apr 22, 2026
7w ago
|
6-K
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.07 (−32.07%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.07 (−32.07%) |
|
Apr 20, 2026
7w ago
|
6-K
| $26.36 $23.37 | ▼ −11.34% | ▼ −12.26% | $17.07 (−35.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access